(Total Views: 465)
Posted On: 08/28/2020 11:52:41 AM
Post# of 653
Re: clambottler #68
combine first post with this information
The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19.
At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.”
This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.
https://relieftherapeutics.com/neurorx-and-re...-covid-19/
_______________________________________________
Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
Jonathan Javitt * and Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
https://www.preprints.org/manuscript/202008.0640/v1
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Hospital course and adverse events. The time to ICU discharge ranged from 1 – 14 days in the 4 of 6 patients so far
discharged from intensive care (Table 2).
Read More: https://investorshangout.com/post/newpost/938...z6WQehYFYA
The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19.
At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.”
This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.
https://relieftherapeutics.com/neurorx-and-re...-covid-19/
_______________________________________________
Rapid Recovery in Six Patients with COVID-19 Respiratory Failure after Treatment with Vasoactive Intestinal Peptide
Jonathan Javitt * and Jihad Youssef
Version 1 : Received: 27 August 2020 / Approved: 28 August 2020 / Online: 28 August 2020 (11:38:23 CEST)
https://www.preprints.org/manuscript/202008.0640/v1
Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.
Hospital course and adverse events. The time to ICU discharge ranged from 1 – 14 days in the 4 of 6 patients so far
discharged from intensive care (Table 2).
Read More: https://investorshangout.com/post/newpost/938...z6WQehYFYA
(1)
(0)Scroll down for more posts ▼
